One of the highest priorities of the Simmons Cancer Center is to efficiently translate scientific discoveries to the clinic in order to reduce cancer morbidity and mortality. U.T. Southwestem has a long tradifion of excellence in the basic sciences and with the recent organizafion of well-defined Cancer Center programs, insfitufional scienfists are responsible for some of the most important recent advances in translatable cancer biology. Early phase Invesfigator-inifiated translafional research trials require significant regulatory, data management and research nursing resources that are not always available through traditional mechanisms in a fimely fashion. Protocol-specific research support provides a mechanism for rapidly translating insfitutional cancer science to the clinic. These funds are intended to support the programmatic priorifies of the Simmons Cancer Center. Criteria used to assess suitability for Protocol-Specific Research support include: 1. Invesfigator-initiated feasibility/Phase I or pilot trial with exceptional scientific merit 2. The trial must meet one or more of the following criteria: a. The agent or concept to be tested is a product of U.T. Southwestern preclinical science. b. The trial will generate data required for external peer-reviewed funding or for development into a larger, multi-institutional phase II or III trial. c. The trial promotes significant interacfion between basic and clinical scienfists to achieve important correlative objecfives. Priorities for this funding are communicated to the Disease Oriented Teams (DOTs) through the bi-monthly DOT leaders meetings and to the Program Leaders at their bi-monthly meefings. Information flows both direcfions at these meefings as DOT leaders can vet invesfigator inifiated protocol ideas and Program leaders can promote agents or molecules ready for clinical evaluafion. Individual DOTs are encouraged to develop and refine protocol concepts responsive to the Cancer Center priorifies and to seek feedback from the Associate Director for Clinical Research early in the development process.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
United States
Zip Code
Wong, Mandy S; Wright, Woodring E; Shay, Jerry W (2014) Alternative splicing regulation of telomerase: a new paradigm? Trends Genet 30:430-8
Chau, Vincent; Lim, S Kyun; Mo, Wei et al. (2014) Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res 74:586-97
Iscla, Irene; Wray, Robin; Wei, Shuguang et al. (2014) Streptomycin potency is dependent on MscL channel expression. Nat Commun 5:4891
Fu, Peng; Johnson, Melissa; Chen, Hong et al. (2014) Carpatamides A-C, cytotoxic arylamine derivatives from a marine-derived Streptomyces sp. J Nat Prod 77:1245-8
Park, Jason Y; Gunpat, Joshua; Liu, Li et al. (2014) Red-shifted emission from 1,2-dioxetane-based chemiluminescent reactions. Luminescence 29:553-8
Gerber, David E; Laccetti, Andrew L; Xuan, Lei et al. (2014) Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 106:
Yang, Liu; Kwon, Junghee; Popov, Yury et al. (2014) Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 146:1339-50.e1
Li, Biaoru; Ding, Lianghao; Yang, Chinrang et al. (2014) Characterization of transcription factor networks involved in umbilical cord blood CD34+ stem cells-derived erythropoiesis. PLoS One 9:e107133
Ludlow, Andrew T; Robin, Jerome D; Sayed, Mohammed et al. (2014) Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution. Nucleic Acids Res 42:e104
King, Kelly A; Gordon-Salant, Sandra; Pawlowski, Karen S et al. (2014) Hearing loss is an early consequence of Npc1 gene deletion in the mouse model of Niemann-Pick disease, type C. J Assoc Res Otolaryngol 15:529-41

Showing the most recent 10 out of 83 publications